Abstract
To the Editor: Subacute cutaneous lupus erythematosus (SCLE) is a distinct subset of lupus erythematosus (LE). Patients have cutaneous manifestations, but rarely have the systemic complications experienced with systemic lupus erythematosus. The skin examination usually consists of photodistributed scaly papules that progress to form psoriasiform or annular plaques.1 Many drugs have been implicated in inducing SCLE, but to our knowledge, there have been no reports of this disease induced by efalizumab (Raptiva).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
